Buchbinder David, Nugent Diane, Vu Dan, Soni Amit, Stites Jill, Hsieh Loan, Puthenveetil Geetha
Division of Hematology, CHOC Children's Hospital and UC Irvine Medical Center, Orange, CA 92868, USA.
Pediatr Transplant. 2012 May;16(3):E69-73. doi: 10.1111/j.1399-3046.2010.01414.x. Epub 2010 Nov 26.
CDA is a heterogeneous group of disorders that result in morphologically abnormal erythroid maturation and ineffective erythropoiesis. Curative therapy for CDA focuses on the use of HSCT using fully matched sibling donors. This is the first report of a Type II CDA patient with severe iron overload who was successfully treated with HSCT using a HLA-matched unrelated donor after aggressive chelation therapy. Given the challenges of HSCT in any patient with CDA and severe iron overload, the role of novel approaches to iron chelation and HSCT is discussed.
先天性红细胞生成异常性贫血(CDA)是一组异质性疾病,可导致形态异常的红系成熟和无效造血。CDA的根治性治疗重点是使用完全匹配的同胞供体进行造血干细胞移植(HSCT)。本文首次报道了一名II型CDA重症铁过载患者,在积极螯合治疗后,使用HLA匹配的无关供体成功进行了HSCT治疗。鉴于HSCT治疗任何CDA合并重症铁过载患者均存在挑战,本文探讨了新型铁螯合方法及HSCT的作用。